Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16626164 | 0.90 | EGLN1 (0.66) | EGLN1GLAHSD17B10GAAHPGD | |
| SCHEMBL626312 | 0.82 | ADORA2A (0.54) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL16626176 | 0.81 | EGLN1 (0.66) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL16626213 | 0.81 | EGLN1 (0.52) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL16626253 | 0.81 | EGLN1 (0.67) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL16626172 | 0.81 | EGLN1 (0.67) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL626735 | 0.80 | EGLN1 (0.66) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL627894 | 0.80 | EGLN1 (0.66) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL627376 | 0.80 | EGLN1 (0.64) | EGLN1ADORA2AGLATSHRHSD17B10 | |
| SCHEMBL626745 | 0.80 | EGLN1 (0.66) | EGLN1ADORA2AGLATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV | 2021-04-13 | — | — | US | disclosed |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-26 | — | — | US | disclosed |
| US-9006251-B2 | 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors | JANSSEN PHARAMCEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| EP-2603502-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021830-A1 | 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975062-B2 | 4-aminoquinazolinyl compounds as prolyl hydroxylase inhibitors | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885ADORA2A 3619/4885GLA 1393/4885 |
| US-20200095234-A1 | 4-AMINOQUINAZOLINYL COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | EGLN1 6/4885ADORA2A 3619/4885GLA 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.